INS and metabolic syndrome: MetS goes from disturbances in the glucose metabolism to comorbidities such as obesity, arterial pathology and dyslipidemia; it finally triggers type 2 diabetes and cardiovascular diseases, illustrated by higher insulin and C-peptide levels.